Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. Journal Abstract

Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.

Publication Date: 2024 Aug

Full Text Sources

Elsevier Science (Free)

ClinicalKey (Free)

Authors

Kristina Jenei; Arianna Gentilini; Alyson Haslam; Vinay Prasad

Abstract

OBJECTIVE

Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in the USA, Canada, Australia, UK, Israel, Brazil, Singapore, and Switzerland to bring promising cancer drugs to patients earlier. We explored the clinical benefit, time to regulatory approval and health technology assessment recommendations, reimbursement outcomes, and monthly treatment prices of cancer drugs reviewed through this initiative.

Source

The Lancet. Oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39004098